Investigational Drug Details
| Drug ID: | D029 |
| Drug Name: | Berberine |
| Synonyms: | -- |
| Type: | Chemical drug |
| DrugBank ID: | DB04115 |
| DrugBank Description: | An alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants. It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal. |
| PubChem ID: | 2353 |
| CasNo: | 2086-83-1 |
| Repositioning for NAFLD: | Yes |
| SMILES: | O(C)c1c2c[n+]3c(cc2ccc1OC)c1c(CC3)cc2c(c1)OCO2 |
| Structure: |
|
| InChiKey: | YBHILYKTIRIUTE-UHFFFAOYSA-N |
| Molecular Weight: | 336.367 |
| DrugBank Targets: | HTH-type transcriptional regulator QacR; Baculoviral IAP repeat-containing protein 5 |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | AMPK activator |
| Therapeutic Category: | Improve insulin resistance |
| Clinical Trial Progress: | Clinical trial completed (NCT04049396) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0463 | NCT04049396 | Not applicable | Not recruiting | No Results Available | 21/07/2019 | 12 December 2020 | Details |
| L0977 | NCT00633282 | Phase 2 | Not recruiting | No Results Available | 03/03/2008 | 19 February 2015 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00030 | 35250593 | Front Pharmacol | Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease. | Details |
| A00413 | 35093393 | Biochem Pharmacol | Targeting lipophagy as a potential therapeutic strategy for nonalcoholic fatty liver disease. | Details |
| A00797 | 34964117 | Compr Physiol | Bile Acids, Gut Microbiome and the Road to Fatty Liver Disease. | Details |
| A00850 | 34948230 | Int J Mol Sci | It Is High Time Physicians Thought of Natural Products for Alleviating NAFLD. Is There Sufficient Evidence to Use Them? | Details |
| A00869 | 34944525 | Biomolecules | A System-Level Mechanism of Anmyungambi Decoction for Obesity: A Network Pharmacological Approach. | Details |
| A01579 | 34686466 | J Integr Med | Berberine mitigates nonalcoholic hepatic steatosis by downregulating SIRT1-FoxO1-SREBP2 pathway for cholesterol synthesis. | Details |
| A01605 | 34681219 | Pharmaceuticals (Basel) | Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach. | Details |
| A01902 | 34566663 | Front Pharmacol | Preclinical Evidence of Berberine on Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Animal Studies. | Details |
| A01996 | 34535644 | Nat Commun | A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. | Details |
| A02108 | 34504563 | Exp Ther Med | Berberine ameliorates nonalcoholic fatty liver disease by decreasing the liver lipid content via reversing the abnormal expression of MTTP and LDLR. | Details |
| A02306 | 34426744 | Evid Based Complement Alternat Med | Targeting miRNA by Natural Products: A Novel Therapeutic Approach for Nonalcoholic Fatty Liver. | Details |
| A02474 | 34360538 | Int J Mol Sci | Diabetes Mellitus and Cardiovascular Diseases: Nutraceutical Interventions Related to Caloric Restriction. | Details |
| A02506 | 34348707 | J Nanobiotechnology | Improving the ameliorative effects of berberine and curcumin combination via dextran-coated bilosomes on non-alcohol fatty liver disease in mice. | Details |
| A02932 | 34192596 | Life Sci | Demethylenetetrahydroberberine alleviates nonalcoholic fatty liver disease by inhibiting the NLRP3 inflammasome and oxidative stress in mice. | Details |
| A03195 | 34094026 | Iran J Basic Med Sci | The therapeutic effects of berberine plus sitagliptin in a rat model of fatty liver disease. | Details |
| A03296 | 34056769 | Phytother Res | Molecular updates on berberine in liver diseases: Bench to bedside. | Details |
| A03453 | 33994854 | Int J Biol Sci | Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver. | Details |
| A03460 | 33992930 | Eur J Med Chem | Natural products and analogs as preventive agents for metabolic syndrome via peroxisome proliferator-activated receptors: An overview. | Details |
| A03630 | 33924725 | Nutrients | The Combination of Berberine, Tocotrienols and Coffee Extracts Improves Metabolic Profile and Liver Steatosis by the Modulation of Gut Microbiota and Hepatic miR-122 and miR-34a Expression in Mice. | Details |
| A03796 | 33861449 | Adv Exp Med Biol | Beneficial Effects of Plant-Derived Natural Products on Non-alcoholic Fatty Liver Disease. | Details |